Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.

Elias S SotirchosNatalia Gonzalez-CalditoBlake E DeweyKathryn C FitzgeraldJeffrey GlaisterAngeliki G FilippatouEsther OgbuokiriSydney FeldmanOhemaa KwakyiHunter RisherCiprian CrainiceanuDzung L PhamPeter C Van ZijlEllen M MowryDaniel S ReichJerry L PrincePeter A CalabresiShiv Saidha

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)

DMT-H treatment may be associated with slower rates of subcortical GM atrophy, especially of the thalamus and putamen. Thalamic and putaminal volumes are promising imaging biomarkers in MS.

Keyphrases

multiple sclerosis
white matter
deep brain stimulation
high resolution
mass spectrometry
ms ms
fluorescence imaging
smoking cessation